Categories Earnings, Health Care

Portola’s stock crashes 12% despite Q1 results beat

Shares of Portola Pharmaceuticals (NASDAQ: PTLA) plummeted 12.7% in morning trade on Wednesday despite the company achieving better-than-expected revenue and earnings for the first quarter of 2019.

Total revenues grew to $22.2 million during the first quarter of 2019 from $6.6 million in the prior-year period. Net product revenues from Andexxa sales totaled $20.3 million while revenue from Bevyxxa sales amounted to $77,000. Collaboration and license revenues were $1.8 million.

On a GAAP basis, net loss attributable to Portola was $78.2 million, or $1.17 per share, compared to $84.2 million, or $1.28 per share, last year. This year’s quarterly results include the effect of two charges related to the US FDA’s approval of the company’s Gen 2 manufacturing process. Adjusted net loss was $68.4 million, or $1.02 per share.

R&D expenses decreased to $35.6 million from $60.1 million in the year-ago quarter, mainly due to the manufacturing costs for Andexxa Gen 2 being capitalized and no longer flowing through R&D.

Portola stated that the full commercial launch of Andexxa in the US is off to a great start and the quarterly results reflected strong demand for the product. The company achieved another long-term growth catalyst with the approval of Ondexxya in Europe.

Portola is making progress with cerdulatinib and the company anticipates defining its safety and efficacy profile through a number of scientific presentations in the second quarter.

Portola’s shares have rallied 79% year to date.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

FDX Earnings: FedEx Q1 adjusted earnings drop; revenue up 5%

Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decline in first-quarter adjusted earnings, despite an increase in revenues. The company also provided guidance for fiscal 2023. Net income, adjusted

Key highlights from Darden Restaurants (DRI) Q1 2023 earnings results

Darden Restaurants, Inc. (NYSE:DRI) reported first quarter 2023 earnings results. Total sales increased 6.1% year-over-year to $2.4 billion, driven by blended same-restaurant sales growth of 4.2%. Net earnings amounted to

ACN Earnings: Key quarterly highlights from Accenture’s Q4 2022 financial results

Accenture (NYSE: ACN) reported fourth quarter 2022 earnings results today. Total revenues were $15.4 billion, up 15% year-over-year in US dollars and up 22.4% in local currency. Net income attributable

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top